Abbott Laboratories stock gains on a USD 385 million settlement

Published on 09/16/2026 at 11:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott Laboratories stock rose after a USD 385 million infant-formula settlement on September 14, 2026. Revenue was USD 12.59 billion in Q2 2026 and the shares opened at USD 103.18.

Modernes Diagnostik-Labor Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 zeigt modernes Diagnostik-Labor mit Wissenschaftlern in weißen Laborkitteln an Analysesystemen, Illustration mit AI erstellt.

Abbott Laboratories stock (ISIN US0028241000) gained after the company agreed to pay about USD 385 million to settle infant-formula claims on September 14, 2026. The shares opened at USD 103.18 on September 15, 2026, according to MarketBeat data referenced by MarketBeat.

Settlement clears a major overhang

As ad hoc news reported on September 15, 2026, Reuters said Abbott Laboratories agreed to pay more than USD 384 million to settle allegations tied to infant formula manufacturing and sales. In the same report, GuruFocus cited a settlement total of USD 384,999,040, a figure that points to the scale of the legal overhang now removed.

The market reaction was immediate. The same article said Abbott stock rose about 1.2 percent after the announcement, and MarketBeat data placed the stock at USD 103.18 on September 15, 2026, still below the 52-week high of USD 137.49 and above the 52-week low of USD 81.97.

Revenue stayed double-digit

Yahoo Finance said on September 14, 2026 that Abbott Laboratories reported second-quarter 2026 revenue of USD 12.59 billion, up 13 percent year on year. The same comparison piece said the company beat analysts' expectations by about 1.1 percent on sales, a useful counterweight to the legal headlines.

That combination matters for investors because it shows a company with current operating growth and a settlement that removes one of the main risks around Abbott Laboratories stock. Yahoo Finance also noted that the shares were up about 14.5 percent since the Q2 2026 report when that analysis was published.

Price stays near the lower half

Per MarketBeat data referenced on September 15, 2026, Abbott Laboratories stock traded at USD 103.18, with a market capitalization of USD 179.0 billion and a consensus analyst target of USD 119.50. The stock sits closer to its 52-week low of USD 81.97 than to its 52-week high of USD 137.49.